SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced the presentation of data from its Phase 1 clinical trial of TCN-032 in healthy volunteers at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA. The trial was designed to evaluate the safety, pharmacokinetics and immunogenicity of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections. TCN-032 was well tolerated throughout the study, with no dose-limiting toxicities or serious adverse events observed, and demonstrated a favorable immunogenicity profile.
